Characteristic

No. of Patients

Evaluable patients

100

Age (median, range)

62.3 (63.0, 22-88 years)

Follow-up ^a (median, range)

29.7 (24.1, 0.01-108 months)

FIGO stage:

1a

4 (4%)

1b

1 (1%)

1c

3 (3%)

IIb

2 (2%)

IIc

4 (4%)

IIIa

1 (1%)

IIIb

2 (2%)

IIIc

76 (75%)

IV

7 (7%)

Histology:

Papillary serous

73 (73%)

Clear cell

7 (7%)

Endometrioid

5 (5%)

Mucinous

2 (2%)

Undifferentiated

3 (3%)

Other (transitional, mixed, carcinosarcoma)

10 (10%)

Grade:

1

7 (7%)

2

9 (9%)

3

84 (84%)

Response to frontline therapy:

Complete response

52 (52%)

Partial response

41 (41%)

Progression

1 (1%)

Unknown

6 (6%)

Recurrences

Recurrence/persistent disease

62 (62%)

Current status:

Alive with no evidence of disease

35 (35%)

Alive with disease

31 (31%)

Died of disease

31 (31%)

Died from other causes

3 (3%)

CT Antigen status (RT-PCR)

SCP-1 positive

15/100 (15%)